JP2008524123A - 治療用栄養組成物又は組合せ、及びそれらの使用方法 - Google Patents

治療用栄養組成物又は組合せ、及びそれらの使用方法 Download PDF

Info

Publication number
JP2008524123A
JP2008524123A JP2007545807A JP2007545807A JP2008524123A JP 2008524123 A JP2008524123 A JP 2008524123A JP 2007545807 A JP2007545807 A JP 2007545807A JP 2007545807 A JP2007545807 A JP 2007545807A JP 2008524123 A JP2008524123 A JP 2008524123A
Authority
JP
Japan
Prior art keywords
glutamine
composition
patient
per liter
selenium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007545807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008524123A5 (https=
Inventor
ダーレン ケイ． ヘイランド
Original Assignee
クリティカル ケア コネクションズ インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリティカル ケア コネクションズ インク filed Critical クリティカル ケア コネクションズ インク
Publication of JP2008524123A publication Critical patent/JP2008524123A/ja
Publication of JP2008524123A5 publication Critical patent/JP2008524123A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007545807A 2004-12-21 2005-12-21 治療用栄養組成物又は組合せ、及びそれらの使用方法 Pending JP2008524123A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63765704P 2004-12-21 2004-12-21
PCT/CA2005/001944 WO2006066404A1 (en) 2004-12-21 2005-12-21 Therapeutic nutrient compositions or combinations and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012006251A Division JP2012107023A (ja) 2004-12-21 2012-01-16 治療用栄養組成物又は組合せ、及びそれらの使用方法

Publications (2)

Publication Number Publication Date
JP2008524123A true JP2008524123A (ja) 2008-07-10
JP2008524123A5 JP2008524123A5 (https=) 2008-08-21

Family

ID=36601322

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007545807A Pending JP2008524123A (ja) 2004-12-21 2005-12-21 治療用栄養組成物又は組合せ、及びそれらの使用方法
JP2012006251A Pending JP2012107023A (ja) 2004-12-21 2012-01-16 治療用栄養組成物又は組合せ、及びそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012006251A Pending JP2012107023A (ja) 2004-12-21 2012-01-16 治療用栄養組成物又は組合せ、及びそれらの使用方法

Country Status (9)

Country Link
US (1) US20080131525A1 (https=)
EP (1) EP1841445A4 (https=)
JP (2) JP2008524123A (https=)
CN (1) CN101084003A (https=)
AU (1) AU2005318832B2 (https=)
BR (1) BRPI0519755A2 (https=)
CA (1) CA2588911C (https=)
WO (1) WO2006066404A1 (https=)
ZA (1) ZA200705824B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004762B2 (en) 2013-05-08 2018-06-26 Gambro Lundia Ab Dialysis formulation
EP3490971A4 (en) * 2016-08-01 2020-02-26 Filament Biosolutions Inc. METHODS OF TREATING AND PREVENTING SIDE EFFECTS OF CANCER TREATMENT
GB201811312D0 (en) * 2018-07-10 2018-08-29 Nuchido Ltd Compositions
CN120420344B (zh) * 2025-07-08 2025-09-05 中国人民解放军总医院第三医学中心 一种眼用药物组合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035056A1 (de) * 2001-10-19 2003-05-01 Basf Aktiengesellschaft Kombination von liponsäure und glutamin in lebens- und arzneimitteln

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
DE4304172A1 (de) * 1993-02-12 1994-08-25 Bayer Ag Fungizide Wirkstoffkombinationen
US5561111A (en) * 1994-12-23 1996-10-01 The University Of Virginia Patent Foundation Stable glutamine derivatives for oral and intravenous rehydration and nutrition therapy
US6022867A (en) * 1996-11-27 2000-02-08 Showa Denko Kabushiki Kaisha Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals
DE69739663D1 (de) * 1996-12-31 2009-12-31 Antioxidant Pharmaceuticals Co Pharmazeutische glutathionpräparate und methoden zu dern verabreichung
US5849335A (en) * 1997-06-02 1998-12-15 Nestec S.A. Composition and method for providing glutamine
WO1999021565A1 (en) * 1997-10-24 1999-05-06 Cornell Research Foundation, Inc. Nutritional supplement for cerebral metabolic insufficiencies
US6649746B1 (en) * 1999-05-07 2003-11-18 University Of Virginia Patent Foundation Biological production of stable glutamine, poly-glutamine derivatives in transgenic organisms and their use for therapeutic purposes
US6805880B1 (en) * 1999-08-20 2004-10-19 Ferrosan A/S Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress
US6890896B1 (en) * 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
AU5625001A (en) * 2000-04-18 2001-10-30 Societe Des Produits Nestle S.A. Nutritional modules
US6479068B1 (en) * 2000-06-30 2002-11-12 Baxter International Inc. Therapeutic nutrient regimen for alleviating mucositis, stomatitis and cachexia in oncology patients
DE10057290B4 (de) * 2000-11-17 2004-01-08 Fresenius Kabi Deutschland Gmbh Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten
US6552076B2 (en) * 2000-12-15 2003-04-22 Mitokor Compounds for altering mitochondrial function and cellular responses
PL363426A1 (en) * 2001-03-09 2004-11-15 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
US6660293B2 (en) * 2001-06-29 2003-12-09 Everett Laboratories, Inc. Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects
JP2003192586A (ja) * 2001-12-27 2003-07-09 Ss Pharmaceut Co Ltd ＩＬ−１β抑制剤
DE10221403A1 (de) * 2002-05-14 2003-12-04 Kyberg Pharma Vertriebs Gmbh & Diätetische und pharmazeutische Zusammensetzungen, ihre Herstellung und ihre Verwendung
US6645514B1 (en) * 2002-12-19 2003-11-11 Access Business Group International, Llc Increasing skin cell renewal with water-soluble Vitamin E

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035056A1 (de) * 2001-10-19 2003-05-01 Basf Aktiengesellschaft Kombination von liponsäure und glutamin in lebens- und arzneimitteln

Also Published As

Publication number Publication date
EP1841445A1 (en) 2007-10-10
JP2012107023A (ja) 2012-06-07
AU2005318832B2 (en) 2011-07-07
WO2006066404A1 (en) 2006-06-29
CA2588911A1 (en) 2006-06-29
AU2005318832A1 (en) 2006-06-29
EP1841445A4 (en) 2010-06-02
BRPI0519755A2 (pt) 2009-03-10
CA2588911C (en) 2013-04-23
US20080131525A1 (en) 2008-06-05
CN101084003A (zh) 2007-12-05
ZA200705824B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
Berger et al. Trace element supplementation after major burns modulates antioxidant status and clinical course by way of increased tissue trace element concentrations
HK74697A (en) Pharmaceutical therapeutic use of glutathione derivatives
CN100518815C (zh) 一种氨基酸组合物
GB2322551A (en) Use of L-citrulline for vasoprotection, relative smooth muscle tone and cell protection
JP2012107023A (ja) 治療用栄養組成物又は組合せ、及びそれらの使用方法
EP0371789B1 (en) Medicament for augmenting fetal hemoglobin
EP0502313B1 (en) Method for insuring adequate intracellular glutathione in tissue
WO2017120311A1 (en) Composition therapy with an iron compound and a citrate compound
ZA200409551B (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone.
Drost et al. Lack of effect of N-acetylcysteine on the release of oxygen radicals from neutrophils and alveolar macrophages
US20070077258A1 (en) ADMINISTRATION OF GLUTATHIONE (REDUCED) VIA INTRAVENOUS OR ENCAPSULATED IN LIPOSOME FOR THE AMELIORATION OF TNF-alpha EFFECTS AND FLU-LIKE VIRAL SYMPTOMS AND TREATMENT AND PREVENTION OF VIRUS
WO2019045989A1 (en) METHODS AND COMPOSITIONS FOR THE ANTIVIRAL USE OF LYSINE SYNTHETIC ANALOGUES AND MIMETICS
EP2323682B1 (en) Compositions comprisng zinc-charged protein for increasing serum antioxidant concentrations
AU4401200A (en) Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
KR20080041675A (ko) 산화형 알부민 저하제
HK1111106A (en) Therapeutic nutrient compositions or combinations and methods of their use
AU2017330451B2 (en) Apoaequorin and vitamin D-containing compositions and methods of using same
KR20110087614A (ko) 산화적 스트레스의 감소를 위한 정맥주사 수액제
EP4487698A1 (en) A micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
US20220273707A1 (en) Compositions and methods for treating canine parvovirus infection
EP2556828B1 (en) Composition for amelioration of hypoalbuminemia
WO2026082800A1 (en) Nutrional composition for treating and/or preventing muscle wasting
WO2025184398A1 (en) Liposomal formulations, and methods of using and preparing thereof
EP3797784A1 (en) Anti-coagulant agent, blood coagulation improving device, blood coagulation improving method, vascular endothelial cell function improving method, and metabolism improving method
BR102022021083A2 (pt) Composição alimentar, uso da referida composição para aumentar a imunidade e ter capacidade de desintoxicação para melhorar fatores de estilo de vida, produto alimentar que compreende a referida composição e kit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110606

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110707

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120222

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120405

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140228